deferoxamine has been researched along with Breast Cancer in 38 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " MCF-7 and MDA-MB-231 breast cancer cells treated with increasing concentrations of the iron chelator deferoxamine were assessed for intracellular iron status, the expression of key proteins involved in iron metabolism, cell viability, growth potential, and apoptosis at different time points following treatment." | 7.88 | High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines. ( Bajbouj, K; Hamad, M; Shafarin, J, 2018) |
| "Mimosine is a toxic nonprotein amino acid that is a major constituent of the tropical legumes Leucaena and Mimosa." | 5.29 | Mimosine blocks cell cycle progression by chelating iron in asynchronous human breast cancer cells. ( Kulp, KS; Vulliet, PR, 1996) |
| " MCF-7 and MDA-MB-231 breast cancer cells treated with increasing concentrations of the iron chelator deferoxamine were assessed for intracellular iron status, the expression of key proteins involved in iron metabolism, cell viability, growth potential, and apoptosis at different time points following treatment." | 3.88 | High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines. ( Bajbouj, K; Hamad, M; Shafarin, J, 2018) |
| "We examined the morphological, proteomic, and metabolic effects induced by two iron chelators-deferoxamine (DFO) and di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT)-on MDA-MB-231 and MDA-MB-157 breast cancer cells." | 3.88 | Lipid accumulation in human breast cancer cells injured by iron depletors. ( Bongarzone, I; Caccia, C; Casalini, P; Crisafi, F; De Bortoli, M; Kumar, V; Maffioli, E; Polli, D; Taverna, E; Tedeschi, G, 2018) |
| "T-47D human breast cancer cells grown in culture medium containing low concentrations of fetal calf serum (FCS) proliferated very slowly, with an accumulation of cells in the G2 phase of the cell cycle, increased polyploid cells, and increased expression of transferrin receptors." | 3.67 | Cell cycle effects of iron depletion on T-47D human breast cancer cells. ( Hedley, DW; Reddel, RR; Sutherland, RL, 1985) |
| "Aminolevulinic acid (ALA) is a prodrug that is metabolized in the heme biosynthesis pathway to produce protoporphyrin IX (PpIX) for tumor fluorescence detection and photodynamic therapy (PDT)." | 1.51 | Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine. ( Braun, A; Chen, B; Howley, R; Kraus, D; Mansi, M; Myers, KA; Palasuberniam, P, 2019) |
| "Iron reversed cytotoxicity to breast cancer cells induced by NO, released from S-nitroso-N-acetyl-penicillamine (NO donor)." | 1.46 | Decreased Iron in Cancer Cells and Their Microenvironment Improves Cytolysis of Breast Cancer Cells by Natural Killer Cells. ( Elliott, RL; Jiang, XP, 2017) |
| "Zirconium-89 has an ideal half-life for use in antibody-based PET imaging; however, when used with the chelator DFO, there is an accumulation of radioactivity in the bone, suggesting that the (89)Zr(4+) cation is being released in vivo." | 1.42 | p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. ( Burton-Pye, BP; Cicek, HT; Deri, MA; Francesconi, LC; Hu, C; Kozlowski, P; Lewis, JS; Ponnala, S, 2015) |
| "In conclusion, breast cancer cells up-regulate the expression of iron importer genes and down-regulate the expression of iron exporter SLC40A1 to satisfy their increased demand for iron." | 1.36 | Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. ( Elliott, RL; Head, JF; Jiang, XP, 2010) |
| "We tested non-hematopoietic human tumors for in vitro sensitivity to either a pair of synergistic IgG antitransferrin (Tf) receptor monoclonal antibodies (MAbs), deferoxamine (DFO) or the combination thereof." | 1.29 | Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. ( Kemp, JD; Kovar, J; Naumann, PW; Stewart, BC, 1995) |
| "Mimosine is a toxic nonprotein amino acid that is a major constituent of the tropical legumes Leucaena and Mimosa." | 1.29 | Mimosine blocks cell cycle progression by chelating iron in asynchronous human breast cancer cells. ( Kulp, KS; Vulliet, PR, 1996) |
| "Treating breast cancer cells with 400 microM mimosine for 24 h inhibited cyclin E- and cyclin A-associated kinase activity by 85% or more, although immunoblots using anti-cyclin A, cyclin E, cdc2, and cdk2 antibodies showed that these key subunits were still present in the cells at pretreatment levels." | 1.29 | Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. ( Green, SL; Kulp, KS; Vulliet, PR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (13.16) | 18.7374 |
| 1990's | 4 (10.53) | 18.2507 |
| 2000's | 13 (34.21) | 29.6817 |
| 2010's | 15 (39.47) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Barrak, NH | 1 |
| Khajah, MA | 1 |
| Luqmani, YA | 1 |
| Jiang, XP | 2 |
| Elliott, RL | 3 |
| Kuban-Jankowska, A | 1 |
| Sahu, KK | 1 |
| Gorska-Ponikowska, M | 1 |
| Tuszynski, JA | 1 |
| Wozniak, M | 1 |
| Bajbouj, K | 1 |
| Shafarin, J | 1 |
| Hamad, M | 1 |
| De Bortoli, M | 1 |
| Taverna, E | 1 |
| Maffioli, E | 1 |
| Casalini, P | 1 |
| Crisafi, F | 1 |
| Kumar, V | 1 |
| Caccia, C | 1 |
| Polli, D | 1 |
| Tedeschi, G | 1 |
| Bongarzone, I | 1 |
| Karimi Shervedani, R | 1 |
| Yaghoobi, F | 1 |
| Torabi, M | 1 |
| Rahsepar, FR | 1 |
| Samiei Foroushani, M | 1 |
| Dassoulas, KR | 1 |
| Mericli, AF | 1 |
| Wang, JS | 1 |
| Lei, SS | 1 |
| Kim, T | 1 |
| Cottler, PS | 1 |
| Lin, KY | 1 |
| Vivier, D | 1 |
| Sharma, SK | 1 |
| Adumeau, P | 1 |
| Rodriguez, C | 1 |
| Fung, K | 1 |
| Zeglis, BM | 1 |
| Palasuberniam, P | 1 |
| Kraus, D | 1 |
| Mansi, M | 1 |
| Braun, A | 1 |
| Howley, R | 1 |
| Myers, KA | 1 |
| Chen, B | 1 |
| Salis, O | 1 |
| Bedir, A | 1 |
| Kilinc, V | 1 |
| Alacam, H | 1 |
| Gulten, S | 1 |
| Okuyucu, A | 1 |
| Picardo, E | 1 |
| Mitidieri, M | 1 |
| Minniti, E | 1 |
| Ambroggio, S | 1 |
| D'Addato, F | 1 |
| Benedetto, C | 1 |
| Gregori, G | 1 |
| Baù, MG | 1 |
| Deri, MA | 1 |
| Ponnala, S | 1 |
| Kozlowski, P | 1 |
| Burton-Pye, BP | 1 |
| Cicek, HT | 1 |
| Hu, C | 1 |
| Lewis, JS | 1 |
| Francesconi, LC | 1 |
| Ozer, U | 1 |
| Rudd, SE | 1 |
| Roselt, P | 1 |
| Cullinane, C | 1 |
| Hicks, RJ | 1 |
| Donnelly, PS | 1 |
| Jung, KO | 1 |
| Youn, H | 1 |
| Lee, CH | 1 |
| Kang, KW | 1 |
| Chung, JK | 1 |
| Lakhal, S | 1 |
| Talbot, NP | 1 |
| Crosby, A | 1 |
| Stoepker, C | 1 |
| Townsend, AR | 1 |
| Robbins, PA | 1 |
| Pugh, CW | 1 |
| Ratcliffe, PJ | 1 |
| Mole, DR | 1 |
| Head, JF | 2 |
| Watts, RN | 1 |
| Richardson, DR | 2 |
| Chong, TW | 1 |
| Horwitz, LD | 2 |
| Moore, JW | 1 |
| Sowter, HM | 1 |
| Harris, AL | 2 |
| Hodges, YK | 1 |
| Antholine, WE | 1 |
| Hoke, EM | 1 |
| Maylock, CA | 1 |
| Shacter, E | 1 |
| Lee, MY | 2 |
| Joung, YH | 2 |
| Lim, EJ | 2 |
| Park, JH | 2 |
| Ye, SK | 2 |
| Park, T | 2 |
| Zhang, Z | 2 |
| Park, DK | 2 |
| Lee, KJ | 2 |
| Yang, YM | 2 |
| Park, EU | 1 |
| Kim, SY | 1 |
| Moon, WK | 1 |
| Ranney, D | 1 |
| Antich, P | 1 |
| Dadey, E | 1 |
| Mason, R | 1 |
| Kulkarni, P | 1 |
| Singh, O | 1 |
| Chen, H | 1 |
| Constantanescu, A | 1 |
| Parkey, R | 1 |
| Ameri, K | 1 |
| Hammond, EM | 1 |
| Culmsee, C | 1 |
| Raida, M | 1 |
| Katschinski, DM | 1 |
| Wenger, RH | 1 |
| Wagner, E | 1 |
| Davis, RJ | 1 |
| Hai, T | 1 |
| Denko, N | 1 |
| Fu, D | 1 |
| Alvarez, MG | 1 |
| Lacelli, MS | 1 |
| Rivarola, V | 1 |
| Batlle, A | 1 |
| Fukuda, H | 1 |
| Seifeddine, R | 1 |
| Dreiem, A | 1 |
| Blanc, E | 1 |
| Fulchignoni-Lataud, MC | 1 |
| Le Frère Belda, MA | 1 |
| Lecuru, F | 1 |
| Mayi, TH | 1 |
| Mazure, N | 1 |
| Favaudon, V | 1 |
| Massaad, C | 1 |
| Barouki, R | 1 |
| Massaad-Massade, L | 1 |
| Koizumi, K | 1 |
| Tonami, N | 1 |
| Hisada, K | 1 |
| Kovar, J | 1 |
| Naumann, PW | 1 |
| Stewart, BC | 1 |
| Kemp, JD | 1 |
| Kulp, KS | 2 |
| Vulliet, PR | 2 |
| Green, SL | 1 |
| Wang, F | 1 |
| Hashimoto, T | 1 |
| Kuwashima, S | 1 |
| Sawada, H | 1 |
| Saiki, N | 1 |
| Kono, A | 1 |
| Yamato, M | 1 |
| Fujioka, M | 1 |
| Di Lollo, F | 1 |
| Morini, PL | 1 |
| Fazzini, G | 1 |
| Niosi, L | 1 |
| Sinha, BK | 1 |
| Katki, AG | 1 |
| Batist, G | 1 |
| Cowan, KH | 1 |
| Myers, CE | 1 |
| Reddel, RR | 1 |
| Hedley, DW | 1 |
| Sutherland, RL | 1 |
| Ward, MC | 1 |
| Roberts, KR | 1 |
| Westwood, JH | 1 |
| Coombes, RC | 1 |
| McCready, VR | 1 |
1 review available for deferoxamine and Breast Cancer
| Article | Year |
|---|---|
The first case of breast cancer in thalassemic patient: case report and review of literature.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltratin | 2015 |
1 trial available for deferoxamine and Breast Cancer
| Article | Year |
|---|---|
Regulation of growth differentiation factor 15 expression by intracellular iron.
Topics: Adenocarcinoma; Anemia, Iron-Deficiency; Basic Helix-Loop-Helix Transcription Factors; Breast Neopla | 2009 |
36 other studies available for deferoxamine and Breast Cancer
| Article | Year |
|---|---|
Hypoxic environment may enhance migration/penetration of endocrine resistant MCF7- derived breast cancer cells through monolayers of other non-invasive cancer cells in vitro.
Topics: Basement Membrane; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; Cocultur | 2020 |
Decreased Iron in Cancer Cells and Their Microenvironment Improves Cytolysis of Breast Cancer Cells by Natural Killer Cells.
Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Chlorides; Deferoxamine; Ferric C | 2017 |
Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
Topics: Aurintricarboxylic Acid; Binding Sites; Breast Neoplasms; Catalase; Cell Proliferation; Cell Surviva | 2017 |
High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deferoxamine; Female; Homeostasis | 2018 |
Lipid accumulation in human breast cancer cells injured by iron depletors.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Deferoxamine; Endoplasmic Reticulum; Female; Humans; | 2018 |
Controlled synthesis of mixed molecular nanostructures from folate and deferrioxamine-Ga(III) on gold and tuning their performance for cancer cells.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Deferoxamine; Drug Delivery Systems; Femal | 2018 |
Treatment With Topical Deferoxamine Improves Cutaneous Vascularity and Tissue Pliability in an Irradiated Animal Model of Tissue Expander-Based Breast Reconstruction.
Topics: Administration, Topical; Animals; Breast Neoplasms; Deferoxamine; Disease Models, Animal; Female; Ma | 2019 |
The Impact of FcγRI Binding on Immuno-PET.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Deferoxamine; Female; Glycosylation; Humans; Immunoconj | 2019 |
Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine.
Topics: Aminolevulinic Acid; Breast Neoplasms; Cell Line, Tumor; Deferoxamine; Epithelial Cells; Female; Fer | 2019 |
The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Cycle Proteins; Deferoxamine; Fema | 2014 |
p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.
Topics: Animals; Breast; Breast Neoplasms; Cell Line, Tumor; Chelating Agents; Deferoxamine; Female; Humans; | 2015 |
The role of Iron on breast cancer stem-like cells.
Topics: Breast Neoplasms; Cell Count; Cell Line, Tumor; Cell Survival; Deferoxamine; Epithelial Cells; Femal | 2016 |
A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies.
Topics: Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Deferoxamine; Diseas | 2016 |
Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells.
Topics: 3T3 Cells; Animals; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Deferoxamine; Ephrin-A | 2017 |
Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Chlorides; D | 2010 |
The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Membrane Permeability; Cell-Free System; Cytosol; De | 2002 |
A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Brea | 2002 |
Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins.
Topics: Breast Neoplasms; Cell Line, Tumor; Deferoxamine; DNA; DNA Replication; Electron Spin Resonance Spec | 2004 |
Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferat | 2005 |
Phosphorylation and activation of STAT proteins by hypoxia in breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Deferoxamine; Female; Humans; Mammary Gla | 2006 |
Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells.
Topics: Anaerobiosis; Animals; Breast Neoplasms; Cell Hypoxia; Chlorocebus aethiops; COS Cells; Cyclin D1; D | 2005 |
Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carbohydrate Sequen | 2005 |
Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway.
Topics: Acetylcysteine; Activating Transcription Factor 3; Amino Acids, Dicarboxylic; Basic Helix-Loop-Helix | 2007 |
Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Deferoxamine; | 2007 |
5-aminolevulinic acid-mediated photodynamic therapy on Hep-2 and MCF-7c3 cells.
Topics: Adenocarcinoma; Aminolevulinic Acid; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; D | 2007 |
Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells.
Topics: Base Sequence; Blotting, Western; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-alpha; Cell Cycle | 2008 |
Deferoxamine mesylate enhancement of 67Ga tumor-to-blood ratios and tumor imaging.
Topics: Animals; Breast Neoplasms; Deferoxamine; Female; Gallium Radioisotopes; Hodgkin Disease; Humans; Lun | 1982 |
Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Deferoxamine; Down-Regulation; Female; Humans; Male; Neopl | 1995 |
Mimosine blocks cell cycle progression by chelating iron in asynchronous human breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cell Survival; Deferoxamine; DNA, Neoplasm; Dose-Respon | 1996 |
Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cell Line; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin- | 1996 |
Antineoplastic drugs that interfere with iron metabolism in cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cisplatin; | 1997 |
Primary breast lymphoma detected with Tc-99m tetrofosmin scintigraphy.
Topics: Adult; Breast Neoplasms; Deferoxamine; Female; Humans; Lymphoma; Octreotide; Organotechnetium Compou | 2001 |
[Desferrioxamine in the diagnosis of hypo-, normo-, and hypersiderotic hyposideremia].
Topics: Adult; Aged; Anemia, Hypochromic; Arthritis, Rheumatoid; Breast Neoplasms; Deferoxamine; Duodenal Ul | 1977 |
Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action.
Topics: Breast Neoplasms; Catalase; Cell Line; Colony-Forming Units Assay; Cyclic N-Oxides; Deferoxamine; Do | 1987 |
Cell cycle effects of iron depletion on T-47D human breast cancer cells.
Topics: Animals; Blood Physiological Phenomena; Breast Neoplasms; Cattle; Cell Cycle; Cell Division; Cell Li | 1985 |
The effect of chelating agents on the distribution of monoclonal antibodies in mice.
Topics: 2,2'-Dipyridyl; Animals; Antibodies, Monoclonal; Breast Neoplasms; Chelating Agents; Deferoxamine; E | 1986 |